MarketAxess控股 MKTX 深 沪
已收盘 10-31 16:00:00 美东时间
160.06
+0.080
+0.05%
华盛通- 最 高162.05
- 今 开159.88
- 成交量 52.87万股
- 最 低 158.655
- 昨 收 159.98
- 总市值 59.80亿
- 52周最高 274.82
- 市盈率 静 21.99
- 换手率 1.42%
- 52周最低 158.28
- 委 比 -43.98%
- 总股本 3736.38万
- 历史最高 592.89
- 量 比 0.88
- 振 幅 2.12%
- 历史最低 -0.72
- 每 手 1
- 风险率 26.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MarketWise, Inc. Announces Receipt of Unsolicited Proposal
MarketWise, Inc. has received an acquisition proposal from Monument & Cathedral Holdings, LLC to acquire all outstanding equity interests at $17.25 per share, contingent on terminating its tax receivable agreement. The board is reviewing the proposal, and no further updates will be provided unless a definitive agreement is reached.
10-30 03:56
Bank Earnings Lift Wall Street, Gold Hits $4,200: What's Moving Markets Wednesday?
Wall Street rose on Wednesday, with investor optimism lifted by strong bank and corporate earnings alongside growing expectations for further Federal Reserve rate cuts — keeping trade concerns sidelined for now.
10-16 01:06
Short sellers' bets rose against S&P 500 financial stocks in September
Average short interest across S&P 500 financial (NYSEARCA:XLF) stocks rose at the end of September, after 1-basis-point drop in August. The short interest rose to 2.04% in September from 2.01% in Au...
10-11 02:23
美股大行评级 | 最高186美元！戴尔科技或多家机构上调目标价； 高盛上调超微公司目标价至210美元
今日重点评级关注：富国银行：维持Kyverna Therapeutics"超配"评级，目标价从24美元升至27美元；Chardan Capital：维持Oculis Holding"买入"评级，目标价从33美元升至51美元
10-09 10:51
美股大行评级 | 最高300美元，AMD获多家大行上调目标价！
今日重点评级关注：Maxim Group：维持Gain Therapeutics"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Icecure Medical"买入"评级，目标价从2美元升至2.5美元
10-08 09:14
Demystifying MarketAxess Holdings: Insights From 9 Analyst Reviews
Across the recent three months, 9 analysts have shared their insights on Market...
10-08 06:00
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
Marker Therapeutics initiated its Off-the-Shelf (OTS) program for multi-antigen recognizing (MAR) T cells, with the first patient treated in the Phase 1 RAPID study. The OTS product targeting four tumor antigens demonstrated encouraging safety data with no treatment-related adverse events. The study focuses on patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), with potential expansion to other indications. The company ...
10-06 11:30
美股大行评级 | 潜在涨幅162.68%！Ocular Therapeutix获JMP证券升目标价至29美元，维持"跑赢大市"评级
今日重点评级关注：JMP证券：维持Ocular Therapeutix"跑赢大市"评级，目标价从20美元升至29美元；汇丰银行：上调Banco BBVA Argentina评级至"买入"，目标价从21美元下调至17美元
10-02 15:08
Morgan Stanley Maintains Overweight on MarketAxess Holdings, Lowers Price Target to $253
Morgan Stanley analyst Michael Cyprys maintains MarketAxess Holdings (NASDAQ:MKTX) with a Overweight and lowers the price target from $274 to $253.
10-02 00:30
罗宾汉即将纳入标普500指数，早盘上涨逾8%
罗宾汉（股票代码：HOOD）股价在周一早盘上涨逾 8%，原因是有消息称该公司即将被纳入标普 500 指数（代码：^GSPC）。 标普道琼斯指数公司（S...
09-08 22:52
